Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

VYNE Therapeutics Concludes Patient Enrolment in Mid-Stage Study Of Skin Inflammation Candidate

VYNE Therapeutics Inc. (NASDAQ:VYNE) has concluded patient enrollment in the Phase 2a study of of its drug candidate FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).

FMX 114 is evaluated in the Phase 2a four weeks segment study for the treatment in patients suffering from atopic dermatitis compared to vehicle control.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.